Prognosis Of Atrial Fibrillation Research Articles

Left atrial remodeling and voltage-guided ablation outcome in persistent atrial fibrillation patients according to CHA2DS2-VASc score

BackgroundCHA2DS2-VASc score-related differences have been reported in atrial fibrotic remodeling and prognosis of atrial fibrillation (AF) patients after ablation. There are currently no data on the efficacy of low voltage zone (LVZ)-guided ablation in persistent AF patients according to CHA2DS2-VASc score. We assessed in a cohort of persistent AF patients the extent of LVZ, the regional distribution of LA voltage and the outcome of LA voltage-guided substrate ablation in addition to PVI according to CHA2DS2-VASc score.Methods138 consecutive persistent AF patients undergoing a first voltage-guided catheter ablation were enrolled. 58 patients with CHAD2DS2-VASc score ≥ 3 and 80 patients with CHAD2DS2-VASc score ≤ 2 were included. LA voltage maps were obtained using 3D-electroanatomical mapping system in sinus rhythm. LVZ was defined as < 0.5 mV.ResultsIn the high CHAD2DS2-VASc score group, LA voltage was lower (1.5 [1.1–2.5] vs. 2.3 [1.5–2.8] mV, p = 0.02) and LVZs were more frequently identified (40% vs. 18%), p < 0.01). Female with CHA2DS2-VASc score ≥ 3 (p = 0.031), LA indexed volume (p = 0.009) and P-wave duration ≥ 150 ms (p = 0.001) were predictors of LVZ. After a 36-month follow-up, atrial arrhythmia-free survival was similar between the two groups (logrank test, P = 0.676).ConclusionsAF patients with CHAD2DS2-VASc score ≥ 3 display more LA substrate remodeling with lower voltage and more LVZs compared with those with CHAD2DS2-VASc score ≤ 2. Despite this atrial remodeling, they had similar and favorable 36 months results after one single procedure. Unlike male with CHAD2DS2-VASc score ≥ 3, female with CHAD2DS2-VASc score ≥ 3 was predictor of LVZ occurrence.

Prognostic Impact of Body Mass Index in Atrial Fibrillation.

Background/Objectives: Contradictory results have been reported regarding the influence of obesity on the prognosis of atrial fibrillation (AF). The present study aimed to explore the potential association of body mass index (BMI) with the clinical outcomes of hospitalized patients with AF. Methods: In this retrospective, post hoc analysis of the MISOAC-AF randomized trial, 1113 AF patients were included and stratified as the following: underweight (BMI < 18 kg/m2), normal weight (BMI 18-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2), and obese (BMI ≥ 30 kg/m2). The primary outcome was all-cause mortality; the secondary composite outcome was any hospitalization related to AF, heart failure (HF), or stroke. Cox regression analysis, survival analysis, and spline curve models were utilized. Results: Of the patients (median age: 76 years (IQR: 13), male: 54.6%), the majority were overweight (41.4%), followed by obese (33%), normal weight (24%), and underweight (1.6%). During a median 31-month follow-up, 436 (39.2%) patients died and 657 (59%) were hospitalized due to AF, HF, or stroke. Underweight, overweight, and obesity groups were significantly associated with an increased risk of all-cause mortality (p-values 0.02, 0.001, and <0.001, respectively), while overweight and obesity were significantly associated with the composite endpoint (p-values 0.01, <0.001, respectively) compared to normal weight. The spline curve analyses yielded that BMIs > 26.3 and > 25 were incrementally associated with all-cause mortality and the composite endpoint, respectively. A J-shaped relationship between BMI and AF prognosis was deduced. Conclusions: In conclusion, in recently hospitalized AF patients, BMI values outside the normal range were independently associated with poorer prognosis; therefore, it is essential that AF patients maintain a normal weight.

Stochastic time series analysis of atrial fibrillatory electrograms in paroxysmal atrial fibrillation

Abstract Background/Introduction Regional dominant frequency and instantaneous frequency modulation of short fractionated atrial electrograms have been associated with ablation targets and the prognosis of atrial fibrillation (AF). However, inconsistent and not fully comprehensible results have been reported. Purpose To construct a simple computational algorithm for the analysis of continuous fibrillatory atrial electrograms and evaluate it in clinical practice, among patients with paroxysmal AF. Methods Before the first cryo-balloon ablation, 3-minute continuous local electrogram recordings during pace-induced AF were obtained by the circumferential catheter from the left atrial appendage (LAA) and each pulmonary vein: left superior (LSPV), left inferior (LIPV), right superior (RSPV) and right inferior (RIPV). Following time- and frequency-domain analysis, non-linear detrended fluctuation analysis (DFA α) with analysis for short-term (DFA α1) and long-term fluctuations (DFA α2) was performed. The signals were detrended by subtracting time series polynomial fit and badpass filtered in the MATLAB environment (cut-off voltage 0.1 mV to avoid scar and artifacts). Results Fifteen patients were studied. Among different atrial areas, higher mean peak rate (pr) along with lower standard deviation of between peaks intervals (sdpp) and root square of peak-to-peak differences (rmppd) were observed in the LAA and left veins (Fig. 1). In patients with longer AF history (&amp;gt; 2 yrs), lower α, α1 and α2 exponents of DFA were observed (Fig. 2). Conclusions This algorithm depicted dissimilar impact on atrial electrical activity between different atrial areas. Patients with longer AF history had less self-similarity in local LAA electrograms. This might indicate possible ablation targets and reveal patients with greater AF burden and worse arrhythmic prognosis.Leftheriotis - Figure 1Leftheriotis - Figure 2

Impact of chronic obstructive pulmonary disease in patients with atrial fibrillation: an analysis from the GLORIA-AF registry.

Chronic obstructive pulmonary disease (COPD) may influence management and prognosis of atrial fibrillation (AF), but this relationship has been scarcely explored in contemporary global cohorts. We aimed to investigate the association between AF and COPD, in relation to treatment patterns and major outcomes. From the prospective, global GLORIA-AF registry, we analysed factors associated with COPD diagnosis, as well as treatment patterns and risk of major outcomes in relation to COPD. The primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACEs). A total of 36 263 patients (mean age 70.1 ± 10.5 years, 45.2% females) were included; 2,261 (6.2%) had COPD. The prevalence of COPD was lower in Asia and higher in North America. Age, female sex, smoking, body mass index, and cardiovascular comorbidities were associated with the presence of COPD. Chronic obstructive pulmonary disease was associated with higher use of oral anticoagulant (OAC) [adjusted odds ratio (aOR) and 95% confidence interval (CI): 1.29 (1.13-1.47)] and higher OAC discontinuation [adjusted hazard ratio (aHR) and 95% CI: 1.12 (1.01-1.25)]. Chronic obstructive pulmonary disease was associated with less use of beta-blocker [aOR (95% CI): 0.79 (0.72-0.87)], amiodarone and propafenone, and higher use of digoxin and verapamil/diltiazem. Patients with COPD had a higher hazard of primary composite outcome [aHR (95% CI): 1.78 (1.58-2.00)]; no interaction was observed regarding beta-blocker use. Chronic obstructive pulmonary disease was also associated with all-cause death [aHR (95% CI): 2.01 (1.77-2.28)], MACEs [aHR (95% CI): 1.41 (1.18-1.68)], and major bleeding [aHR (95% CI): 1.48 (1.16-1.88)]. In AF patients, COPD was associated with differences in OAC treatment and use of other drugs; Patients with AF and COPD had worse outcomes, including higher mortality, MACE, and major bleeding.

Exploring postoperative atrial fibrillation after non-cardiac surgery: mechanisms, risk factors, and prevention strategies.

Atrial fibrillation (AF) stands as the most prevalent persistent arrhythmia and a common complication after surgical procedures. Although the majority of non-cardiac surgery patients experience postoperative AF (POAF) and the condition is typically self-limited and asymptomatic, its detrimental impact on patient outcomes, prolonged hospitalization, and heightened risk of stroke and overall mortality has become increasingly evident. Of significant concern, POAF emerges as a noteworthy risk factor for stroke, myocardial infarction, and mortality in comparison to patients with non-surgical atrial fibrillation. Multiple studies have corroborated the association between POAF and an elevated risk of stroke and mortality. The development of postoperative atrial fibrillation is multifactorial, with the inflammatory response being a primary contributor; additionally, factors such as hypovolemia, intraoperative hypotension, anemia, trauma, and pain can trigger POAF. Risk factors for POAF in non-cardiac surgery primarily relate to age, hypertension, obesity, prior cardiac disease, obstructive sleep apnea, and male sex. Prophylactic treatment with β-blockers, amiodarone, or magnesium has demonstrated efficacy, but further trials are warranted, especially in high-risk populations. This review provides an account of the incidence rate, pathophysiology, and prognosis of atrial fibrillation after non-cardiac surgery, elucidates the underlying mechanisms of its occurrence, and explores various preventive strategies investigated in this domain.

Refining the prognosis of patients with AF using 3D transesophageal echocardiography of the left atrial appendage

Abstract Background Left atrial (LA) volume is considered an echocardiographic marker of thrombosis risk and prognosis in atrial fibrillation (AF). Limited data is available on the prognostic value of left atrial appendage (LAA) volume in AF as evaluated with three-dimensional (3D) transoesophageal echocardiography (TEE). Purpose We hypothesized that 3D LAA volume is associated with prognosis in patients hospitalized with AF. Methods We prospectively evaluated 206 patients hospitalized for AF with two-dimensional transthoracic echocardiography (TTE) and 3D TEE of the LAA within 24 hours of admission. 3D parameters were analysed off-line using Tomtec software (4D Cardio-View, Generic Volume, Philips). The primary composite outcome was all-cause death during at 2 years follow up. Results The median age of the study group was 66.3 ± 11.5 years with 129 (62.6%) men. In the global population, at admission, the median 3D LAAV was 9.02 (6.96-12.15) ml. Patients were divided into two groups according to the median 3D LAAV: Group 1: LAAV &amp;lt; 9ml (103 patients) and Group 2: LAAV ≥ 9ml (103 patients). Patients with LAAV ≥ 9ml had more frequently a history of heart failure and chronic obstructive pulmonary disease. There were no significant intergroup differences in CHA2DS2-VASc score. Patients with LAAV ≥ 9ml had higher values of BNP and CRP and lower LVEF, higher LA volumes, higher E/e’, lower LAA emptying flow velocity, and higher 3D ES LAA ostium area. There were no statistical differences in LAA spontaneous echo contrast and LAA morphology between groups (Table 1). Kaplan–Meier curves demonstrated a significant difference in survival according to the 3D ES LAAV: 3 deaths occurred in the group with 3D ES LAA volume &amp;lt; 9mL and 11 in the group with 3D ES LAA Volume≥9mL (p=0.0315) (Figure 1). Conclusion Among LAA parameters, 3D LAA end-systolic volume is significantly associated with a worse outcome in patients with AF. Further investigations are needed to evaluate this unique parameter against usual geometric and functional LA/LAA parameters.

Artificial Intelligence in the Image-Guided Care of Atrial Fibrillation.

Atrial fibrillation arises mainly due to abnormalities in the cardiac conduction system and is associated with anatomical remodeling of the atria and the pulmonary veins. Cardiovascular imaging techniques, such as echocardiography, computed tomography, and magnetic resonance imaging, are crucial in the management of atrial fibrillation, as they not only provide anatomical context to evaluate structural alterations but also help in determining treatment strategies. However, interpreting these images requires significant human expertise. The potential of artificial intelligence in analyzing these images has been repeatedly suggested due to its ability to automate the process with precision comparable to human experts. This review summarizes the benefits of artificial intelligence in enhancing the clinical care of patients with atrial fibrillation through cardiovascular image analysis. It provides a detailed overview of the two most critical steps in image-guided AF management, namely, segmentation and classification. For segmentation, the state-of-the-art artificial intelligence methodologies and the factors influencing the segmentation performance are discussed. For classification, the applications of artificial intelligence in the diagnosis and prognosis of atrial fibrillation are provided. Finally, this review also scrutinizes the current challenges hindering the clinical applicability of these methods, with the aim of guiding future research toward more effective integration into clinical practice.

Impact of gender on left atrial low-voltage zones in patients with persistent atrial fibrillation: results of a voltage-guided ablation.

Gender-related differences have been reported in atrial fibrotic remodeling and prognosis of atrial fibrillation (AF) patients after ablation. We assessed in persistent AF the regional distribution of left atrial (LA) bipolar voltage and the extent of low-voltage zones (LVZ) according to gender as well as the results of a voltage-guided substrate ablation. Consecutive patients who underwent a voltage-guided AF ablation were enrolled. LA endocardial voltage maps were obtained using a 3D electro-anatomical mapping system in sinus rhythm. LVZ was defined as <0.5 mV. A total of 115 patients were enrolled (74 men, 41 women). The LA bipolar voltage amplitude was twice lower in the whole LA (p < 0.01) and in each atrial region in women compared with men, whereas the LA indexed volume was similar. LVZ were found in 56.1% of women and 16.2% of men (p < 0.01). LVZ were also more extensive in women (p = 0.01), especially in the anterior LA. Atrial voltage alteration occurred earlier in women than in men. In a multivariate analysis, the female sex (OR 12.99; 95% CI, 3.23-51.63, p = 0.0001) and LA indexed volume (OR 1.09; 95% CI, 1.04-1.16, p = 0.001) were predictive of LVZ. Atrial arrhythmia-free survival was similar in men and women 36 months after a single ablation procedure. The study reports a strong relationship between the female gender and atrial substrate remodeling. The female gender was significantly associated with higher incidence, earlier occurrence, and greater extent of LVZ compared with men. Despite the female-specific characteristics in atrial remodeling, LVZ-guided ablation may improve the AF ablation outcome in women.

Rural-urban and geographical differences in prognosis of atrial fibrillation in Finland: a nationwide cohort study.

Rural-urban disparities have been reported in the outcomes of cardiovascular diseases. We assessed whether rural-urban or other geographical disparities exist in the risk of ischemic stroke (IS) and death in patients with atrial fibrillation (AF) in Finland. The registry-based FinACAF cohort study covers all patients with AF from all levels of care in Finland from 2007 to 2018. Patients were divided into rural-urban categories and into hospital districts (HDs) based on their municipality of residence. We identified 222,051 patients (50.1% female; mean age 72.8 years; mean follow-up 3.9 years) with new-onset AF, of whom 15,567 (7.0%) patients suffered IS and 72,565 (32.7%) died during follow-up. The crude IS rate was similar between rural and urban areas, whereas the mortality rate was lower in urban areas (incidence rate ratios (IRRs) with 95% confidence intervals (CIs) 0.97 (0.93-1.00) and 0.92 (0.91-0.93), respectively). However, after adjustments, urban residence was associated with slightly higher IS and mortality rates (IRRs with 95% CIs 1.05 (1.01-1.08) and 1.06 (1.04-1.07), respectively). The highest crude IS rate was in the East Savo HD and the lowest in Åland, whereas the highest crude mortality rate was in the Länsi-Pohja HD and the lowest in the North Ostrobothnia HD (IRRs with 95% CIs compared to Helsinki and Uusimaa HD for IS 1.46 (1.28-1.67) and 0.79 (0.62-1.01), and mortality 1.24 (1.16-1.32) and 0.97 (0.93-1.00), respectively. Rural-urban differences in prognosis of AF in Finland appear minimal, whereas considerable disparities exist between HDs.

Clinical Application of the HCM-AF Risk Score in the Prediction of Clinical Outcomes of Polish Patients with Hypertrophic Cardiomyopathy.

The recently introduced HCM-AF Risk Calculator allows the prognosis of atrial fibrillation (AF) occurrence in hypertrophic cardiomyopathy (HCM) patients. The aim of this study was to assess the clinical application of the HCM-AF Risk Score in the prediction of the clinical outcomes of Polish patients. The study included 92 patients (50.0% female, median age 55 years), with a baseline sinus rhythm diagnosed between 2013 and 2018. The analysis involved the incidence of clinical characteristics and outcomes, total mortality, rehospitalisation, and the course of heart failure (HF). According to the HCM-AF Risk Score, the HCM population was stratified into three subgroups, with a low (13/14.2%), intermediate (30/32.6%), and high risk of AF (49/53.2%). Subgroups differed significantly: the high-risk subgroup was older, had a higher body mass index (BMI), and more advanced signs of left ventricular (LV) hypertrophy and left atrium (LA) dilatation. The registered AF incidence was 31.5% and 43.5% in the 2- and 5-year follow-ups, and it was significantly higher than in the HCM-AF Risk Score population, which had 4.6% in the 2-year follow-up, and 10.7% in the 5-year follow-up. In the whole population, the AF incidence in both the 2- and 5-year follow-ups revealed a strong correlation with the HCM-AF Risk Score (r = 0.442, p < 0.001; r = 0.346, p < 0.001, respectively). The clinical outcomes differed among the subgroups: the total mortality was 15.4% vs. 20.0% vs. 42.9% (p < 0.05); rehospitalisation was 23.1% vs. 53.3% vs. 71.4% (p < 0.05). The highest HF progression was in the high-risk subgroup (36.7%). Regardless of the high results of the HCM-Risk Score in Polish patients, the score underestimates the real-life high level of AF incidence. The HCM-AF Risk Score seems to be useful in the prediction of the general clinical outcomes in HCM patients.

Variation evaluation of biometric and sonographic parameters on left atrial strain values

Abstract Funding Acknowledgements Type of funding sources: None. Introduction Speckle tracking echocardiography is an upcoming modality to quantify left atrial function. Left atrial function is disturbed in many disease and left atrial systolic strain (LASr) has already been associated with the prognosis of atrial fibrillation and with the degree of diastolic dysfunction. Some modifying parameters have been identified in relatively small studies. Purpose We aim to assess the influence of known and some unknown biometric and sonographic parameters on LASr values in a large cohort. Methods This prospective cohort study included 211 individuals and assessed general sonographic parameters and LASr. Patients included had normal ejection fraction (≥50%), reasonable image quality with frame rate ≥50FPS and no significant valvular heart disease. The sonographic parameters collected were left ventricular ejection fraction, global longitudinal strain (GLS) and Left atrial volume Index (LAVI). Speckle tracking analysis was done offline by semiautomatic contour detection and R-R gating was used. Results Mean LASr was 35.5 ± 11%. There were significant differences in LASr for age, global longitudinal strain (GLS), left atrial volume Index (LAVI) and vendor (GE versus Philips). LASr was significantly lower in the oldest groups (60–69jr and 70–84jr) and decreasing with progression of LAVI. LASr was significantly lower when the vendor Philips was used compared to GE. Gender was not associated with a change in LASr. Conclusion This study shows a significant influence of ageing, LAVI, GLS and vendor on left atrial strain values. The significant difference in LASr was probably due to a significant difference in frame rate between the two vendors used.

PO-05-200 GENDER DISPARITIES IN MANAGEMENT AND OUTCOMES OF ATRIAL FIBRILLATION IN A MODERN LOUISIANA COHORT

Female gender is associated with a lower lifetime risk of developing atrial fibrillation (AF) when compared to males. Other gender differences in atrial fibrillation comorbidities, treatments, and outcomes have been described with often conflicting results. We sought to investigate gender differences in comorbidities, treatments, and outcomes of atrial fibrillation patients from a recent Louisiana population. Data on patients aged ≥18 years diagnosed with atrial fibrillation between January 2010 and December 2019 was pulled from the Research Action for Health Network database (REACHnet). The primary outcome was defined as the first occurrence of ischemic stroke, transient ischemic attack (TIA), intracranial bleeding, gastrointestinal bleeding, hospitalization, or death. Chi-squared test was used to study categorical variables. Poisson regression was used to examine the effect of gender on outpatient visits per year, adjusted for comorbidities. 2592 patients were included in this study, 35.1% of whom were females. Female patients were younger (62.2 vs 63.3 years p <0.001), had less coronary artery disease (OR=0.68, p <0.001), and less chronic kidney disease (OR=0.89, p=0.005), but a more frequent stroke history (OR=1.4, p<0.001) at baseline (figure). Females were less likely to receive antiarrhythmic drug therapy (AAD) (OR=0.75, p=0.018). Among those who received AADs, female patients were less likely to receive amiodarone (OR=0.69, p=0.003), and more likely to receive flecainide (OR=3.45, p=0.048). Patients with at least 1 non-gender CHA2DS2-VASc risk factor had similar odds of receiving oral anticoagulation in general, and similar odds for receiving direct oral anticoagulants in particular. Females had one more outpatient visit per year than males did, even after accounting for comorbidity differences (p <0.001). Female patients had higher odds of achieving our primary outcome of stroke, TIA, intracranial bleeding, gastrointestinal bleeding, hospitalization, or death (OR=1.19, p=0.041). Female atrial fibrillation patients have a different comorbidity profile than their male counterparts. We found persistent gender disparities in the management and prognosis of atrial fibrillation in a modern Louisiana population.

Prevalence and prognosis of atrial fibrillation in a hypertensive population: A prospective cohort study.

Identifying risk factors for atrial fibrillation (AF) and evaluating their impact are essential to avoid the occurrence of adverse events. However, few studies to date have explored the prevalence, risk factors, and prognosis of AF in hypertensive patients. The objective of this study was to investigate the epidemiology of AF in a hypertensive population and determine the relationship between AF and all-cause mortality. At baseline, a total of 8541 Chinese patients with hypertension were enrolled from the Northeast Rural Cardiovascular Health Study. A logistic regression model was established to assess the relationship between blood pressure and AF, and Kaplan-Meier survival curve analysis and multivariate Cox regression were used to explore the relationship between AF and all-cause mortality. Meanwhile, subgroup analyses illustrated the robustness of results. This study found that the overall prevalence rate of AF was 1.4% in its Chinese hypertensive population. After adjusting for the confounding factors, every standard deviation increase in diastolic blood pressure (DBP) was associated with a 37% increase in the prevalence of AF (95% confidence interval: 1.152-1.627, p<.001). Compared to hypertensive patients without AF, those with AF had an increased risk of all-cause mortality (hazard ratio=1.866, 95% confidence interval: 1.117-3.115, p=.017) in the adjusted model. The results show that the burden of AF is quite large in rural-dwelling Chinese hypertensive patients. Focusing on the control of DBP to prevent the occurrence of AF can be helpful. Meanwhile, AF increases risk of all-cause mortality in hypertensive patients. Our results indicated a huge burden of AF. Considering that most of the risk factors of AF were unmodifiable in hypertensive individuals and given their high risk of mortality, long-term interventions, including AF education, timely screening, and widespread use of anticoagulant drugs, should be emphasized in hypertensive populations.

Modeling sex differences in human atrial myocyte structural and Ca2+ handling properties: Impact on Ca2+-driven arrhythmia.

Substantial sex differences have been reported in the prevalence, pathophysiology, treatment, and prognosis of atrial fibrillation (AF), the most common cardiac arrhythmia. Knowledge of sex differences in the underlying arrhythmogenic substrate may improve therapy. Recent experimental studies revealed differences in cell geometry, transverse-axial tubule system (TATS) density, and expression, function, and phosphorylation status of Ca2+ handling proteins in female vs. male atrial myocytes, and in their remodeling in AF. However, it remains unknown how these sex-dependent differences contribute (individually or collectively) to arrhythmia propensity in females vs. males. Here, we used our new human atrial myocyte model coupling electrophysiology and spatially-detailed Ca2+ cycling governed by the TATS to integrate these sex-specific features and build sex-specific models of both normal sinus rhythm (nSR) and AF conditions. We tested the responses of the models to a pace-pause protocol and found that in nSR the female myocyte model displays 1) higher Ca2+ spark frequency, and 2) greater and more frequent spontaneous Ca2+ release (SCR) compared to male. These sex differences in Ca2+-driven arrhythmias are exacerbated in AF conditions. A systematic parametric study revealed the precise contribution of each sex-dependent change (i.e., TATS density, cell dimension, and Ca2+-handling protein expression or function) to SCR and Ca2+ spark properties. Both sparse TATS and changes in Ca2+-handling proteins (i.e., larger L-type Ca2+ current, reduced calsequestrin expression, higher RyR phosphorylation, and increased sarcoplasmic reticulum Ca2+-ATPase) promote greater Ca2+-driven arrhythmia in female myocytes, which was slightly attenuated by the smaller cell dimension vs male myocytes. Our study demonstrates the interactive contributions of subcellular structural and ionic sex differences to intracellular Ca2+ instability and provides novel model-based mechanistic insight that may guide future therapeutic sex-specific anti-AF strategies.

ANGPTL4 suppresses the profibrogenic functions of atrial fibroblasts induced by angiotensin II by up-regulating PPARγ.

The present study's objective was to investigate the association between angiopoietin-like 4 (ANGPTL4) levels and the prognosis of Atrial fibrillation (AF), the causative effect in angiotensin II- (Ang II) induced AF, and its underlying mechanisms. Baseline serum ANGPTL-4 concentrations were measured in 130 patients with AF. Rat atrial fibroblasts were isolated from 14-day-old SD rats and transfected with Ang II treatment. Transfected cells were divided into: The control group, ANGPTL4-OE group, Ang II group, and Ang II+ANGPTL4-OE group. Transfected cells were used to analyze fibroblasts' proliferation, migration, and collagen production at the cellular level. RT-qPCR and western blotting evaluated the ANGPTL4-targeted gene and PPARγ-Akt pathway. In patients with AF, serum ANGPTL4 concentrations decreased significantly compared with the healthy group. ANGPTL4 mRNA and protein expressions were significantly down-regulated in Ang II-induced cardiac fibroblasts. ANGPTL4 overexpression potentially attenuated Ang IIinduced fibroblast proliferation, migration, and collagen production in atrial tissue. ANGPTL4 inhibited the signaling proteins, such as PPARγ, α-SMA, and Akt. Our experimental data speculate that ANGPTL4 is a key factor in regulating AF progression. Therefore, increasing ANGPTL4 expression could be an effective strategy for AF treatment.

The prognosis of atrial fibrillation in ST-segment elevation acute myocardial infarction in Algeria

The prognosis of atrial fibrillation in ST-segment elevation acute myocardial infarction in Algeria

The Relationship between Uric Acid and the Development, Complication, and Prognosis of Atrial Fibrillation: The Views from a Clinical Study.

A large number of studies suggest that uric acid (UA) is related to the occurrence, complications, and prognosis of atrial fibrillation (AF). However, the guidelines did not clearly elaborate on this issue. The current research results need to be summarized to analyze the association between UA and AF. This study found that in the current clinical research on the relationship between UA and AF, studies mainly focus on the development or complications of AF. A lot of repetitive work does not deepen awareness of this question. In contrast, studies investigating the effects of UA-lowering therapy on the management of AF are limited. The only reports deny the protective effect of UA-lowering therapy. For now, we suggest that UA is close to the occurrence and progression of AF; therefore, it may have important significance as a clinical marker. The role of UA-lowering therapy in the management of AF is one of the next key issues to be explored. It will be a meaningful topic to focus on the latest research on AF ablation and to conduct a secondary analysis to explore the prognostic impact of UA on the latest treatment methods for AF. Multiomics techniques may allow us to have a deeper understanding of the role of UA in AF management in the future.

Prognosis of atrial fibrillation with or without comorbidities. Analysis of younger adults from a nationwide database

Abstract Background “Lone AF” may be defined as AF in younger adults (age &amp;lt;60 years) and lack of obvious associated CV or extra CV conditions. However, current ESC guidelines indicate that the term of “Lone AF” is potentially confusing and should be abandoned because a cause may be present in every patient. In addition, studies on prognosis of “Lone AF” are inconsistent, likely as the result of the heterogeneity in definitions, comorbidities, study population and duration of follow-up. We aimed to assess the prognosis of patients with AF with or without cardiac or extra cardiac concomitant conditions. Participants and methods From the French administrative hospital-discharge PMSI database (Programme de Médicalisation des Systèmes d'Information) covering hospital care and representative of the whole French population, all consecutive patients with AF diagnosis hospitalized between 2011 and 2020 were identified. Patients were classified into four groups: 1) &amp;gt;60 yo; 2) with known cardiac disease (KCD group); 3) with extra cardiac comorbidities (ECC); and 4) AF without KCD or ECC (“Lone AF”). Results Altogether 2,435,541 patients were identified, from which 2203,702 patients aged &amp;gt;60 years and 231,839 patients aged &amp;lt;60 years [with KCD (55.2%), with ECC (14.7%) and with “Lone AF” (30.1%)]. During follow-up the incidences of all-cause and CV deaths were 13.7%, 5.7%, 6.2% and 2.3%, and 4.2%, 1.7%, 0.8% and 0.3% in the older than 60 yo group, KCD group, ECC group and “Lone AF” AF group, respectively. In the age and sex-adjusted analysis (patients &amp;lt;60 yo), patients with AF and KCD had worse outcomes than patients with “Lone AF” for all major cardiac events (see figures). Conclusion There are three distinct prognostic criteria based on the presence or not of HD or extra cardiac concomitant comorbidities. Patients in the so-called “Lone AF” group remain severe in terms of CV events but still with a lower incidence than the patient with associated KCD or ECC. The presences of KCD or ECC make it possible to distinguish a profile in terms of events that are very different from the patients. Funding Acknowledgement Type of funding sources: None.

Potential of comorbidity indices and CHA2DS2-VASc to predict ischemic stroke and mortality in patients with atrial fibrillation: a validation study

Abstract Background Atrial fibrillation represents a large health burden and increases the risk of ischemic stroke and mortality. A large proportion of atrial fibrillation patients also has other comorbidities. It remains unknown whether comorbidity burden summarized as a comorbidity score can predict ischemic stroke and mortality after atrial fibrillation. In an aging population burdened with comorbidities, it thus has become increasingly important to understand the impact of comorbidity burden on the prognosis of atrial fibrillation. Purpose We examined the ability of the Danish Comorbidity Index for Acute Myocardial Infarction (DANCAMI), the Charlson Comorbidity Index (CCI), the Elixhauser Comorbidity Index (ECI), and the CHA2DS2-VASc to predict ischemic stroke and all-cause mortality within one year after atrial fibrillation or flutter. Methods We identified all patients with a first-time atrial fibrillation or flutter hospital diagnosis in Denmark from 2000 through 2015 (n=318,939). We identified all comorbidities in each index using hospital diagnoses in the 10 years before diagnosis of atrial fibrillation or flutter. For each comorbidity index, we calculated Harrell's C-Statistic to predict ischemic stroke, all-cause mortality, and cause-specific mortality due to cardiovascular diseases and cancer within one year after atrial fibrillation or flutter. We also calculated hazard ratios of the association of the DANCAMI comorbidities not included in the CCI with ischemic stroke and all-cause mortality within one year after atrial fibrillation or flutter, after conditioning on age, sex, and all CCI comorbidities. Results The C-Statistic to predict ischemic stroke was 0.64 (95% confidence interval [CI]: 0.63–0.64) for DANCAMI, 0.63 (95% CI: 0.63–0.64) for CCI, 0.63 (95% CI: 0.63–0.64) for ECI, and 0.64 (95% CI: 0.63–0.64) for CHA2DS2-VASc. The C-Statistic to predict all-cause mortality was 0.74 (95% CI: 0.74–0.75) for DANCAMI, 0.74 (95% CI: 0.73–0.74) for CCI, 0.73 (95% CI: 0.72–0.73) for ECI, and 0.69 (95% CI: 0.69–0.69) for CHA2DS2-VASc. Among the DANCAMI comorbidities not included in the CCI, five predicted increased risk of ischemic stroke (epilepsy, alcohol and drug abuse, schizophrenia, affective disorder, and chronic kidney disease) and eight predicted increased risk of all-cause mortality (coagulopathy, neurodegenerative disorder, epilepsy, alcohol and drug abuse, schizophrenia, affective disorder, chronic kidney disease, and chronic pancreatitis). Compared with all-cause mortality, DANCAMI was better at predicting mortality due to cardiovascular diseases (C-Statistic=0.79, 95% CI: 0.79–0.80) and cancer (C-Statistic=0.78, 95% CI: 95% CI: 0.76–0.80) Conclusion In patients with first-time atrial fibrillation or flutter, no comorbidity index predicted ischemic stroke well. However, DANCAMI predicted all-cause mortality on a par with the CCI and the ECI and better than CHA2DS2-VASc. Funding Acknowledgement Type of funding sources: None.

Do Elderly Patients with Atrial Fibrillation Have Comparable Ablation Outcomes Compared to Younger Ones? Evidence from Pooled Clinical Studies.

Background: Age is an independent risk factor of the progress and prognosis of atrial fibrillation (AF). However, ablation outcomes between elderly and younger patients with AF remain elusive. Methods: Cochrane Library, Embase, PubMed, and Web of Science were systematically searched up to 1 April 2022. Studies comparing AF ablation outcomes between elderly and younger patients and comprising outcomes of AF ablation for elderly patients were included. Trial sequential analysis (TSA) was performed to adjust for random error and lower statistical power in our meta-analysis. Subgroup analysis identified possible determinants of outcome impact for elderly patients after ablation. Moreover, linear and quadratic prediction fit plots with confidence intervals were performed, as appropriate. Results: A total of 27 studies with 113,106 AF patients were eligible. Compared with the younger group, the elderly group was significantly associated with a lower rate of freedom from AF (risk ratio [RR], 0.95; p = 0.008), as well as a higher incidence of safety outcomes (cerebrovascular events: RR, 1.64; p = 0.000; serious hemorrhage complications: RR, 1.50; p = 0.035; all-cause death: RR, 2.61; p = 0.003). Subgroup analysis and quadratic prediction fit analysis revealed the follow-up time was the potential determinant of freedom from AF for elderly patients after AF ablation. Conclusions: Our meta-analysis suggests that elderly patients may have inferior efficacy and safety outcomes to younger patients with AF ablation. Moreover, the follow-up time may be a potential determinant of outcome impact on freedom from AF for elderly patients after AF ablation.